• VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study

  • VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles

  • VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy

  • VolitionRx Granted Its Second U.S. Patent

  • VolitionRx to Present at Two Conferences in November

  • VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

  • VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

  • VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

  • VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

  • VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

  • VolitionRx Granted Its First U.S. Patent

  • VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial

  • VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

  • VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015

  • VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer

  • VolitionRx Announces Second Quarter 2015 Financial Results and Business Update

  • VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET

  • VolitionRx to Present at Wedbush PacGrow Healthcare Conference

  • VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs

  • VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar

  • VolitionRx Expands Scientific Advisory Board

  • VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe

  • VolitionRx to Present at Two Upcoming Investor Conferences

  • VolitionRx CEO Cameron Reynolds to Present Informational Webinar

  • VolitionRx Announces First Quarter 2015 Financial Results and Business Update

  • VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers

  • VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET

  • VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps

  • VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

  • VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology

  • VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent

  • VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering

  • VolitionRx Limited Prices Public Offering of Common Stock

  • VolitionRx Begins First Ovarian Cancer Detection Study

  • Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus